Brought to you by 
ZymoGenetics licenses autoimmune products to Serono
02 Dec 2015
Executive Summary
Serono licensed rights to two autoimmune programs from ZymoGenetics (Novo Nordisk spin-off; developing therapeutic proteins). ZymoGenetics stands to receive up to $52.5mm in license fees and milestone payments, plus sales royalties.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com